Gonococci – Pathogens of Growing Importance. Part 2. Virulence Factors, Antimicrobial Resistance and Vaccine Development
, y | 03 jul 2024
Acerca de este artículo
Publicado en línea: 03 jul 2024
Páginas: 113 - 125
Recibido: 01 may 2024
Aceptado: 01 jun 2024
DOI: https://doi.org/10.2478/am-2024-0010
Palabras clave
© 2024 Joanna Białecka et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Fig. 1.
Fig. 2.
Fig. 3.
Research projects on gonorrhoea vaccines approved by National Institutes of Health USA (National Institutes of Health USA, 2024.)
| Project | Organization Project Leader(s) |
|---|---|
| The Gonorrhoea Vaccine Cooperative Research Center | HENRY M. JACKSON FDN FOR THE ADV MIL/MED Ann E. Jerse |
| Proteomics-Driven Reverse Vaccinology for Gonorrhoea | OREGON STATE UNIVERSITY Aleksandra E. Sikora |
| A Novel Sublingual Vaccine to Prevent |
VIRTICI, LLC Neil A. Fanger, |
| STI Clinical Trials Group: Phase 2 Clinical Trial to Evaluate a Vaccine Candidate for |
UNIVERSITY OF ALABAMA AT BIRMINGHAM Edward Hook |
| Pre-clinical Vaccine Development for Emerging and Re-emerging Infectious Diseases | NIAID EXTRAMURAL ACTIVITIES Wing Pui Kong |
| Starve and Kill: Engineered Antigens Targeting Nutrient Acquisition Pathways Essential for Gonococcal Infection and Disease | GEORGIA STATE UNIVERSITY Cynthia N. Cornelissen |
| Development of nucleic acid-based vaccines against gonorrhoea | UNIVERSITY OF MASSACHUSETTS MED SCH WORCESTER Lisa Ann Lewis, Li Li, Sanjay Ram |
| VesiVax Vaccine Formulation Against |
MOLECULAR EXPRESS, INC. Gary Fujii |
| A novel vaccine against multidrug-resistant gonorrhoea | UNIVERSITY OF MASSACHUSETTS MED SCHOOL WORCESTER Sanjay Ram, Peter A. Rice |
| Production of a Gonococcal Vaccine for Countering Antimicrobial Resistance | UNIVERSITY OF CALGARY Anthony B. Schryvers, Scott D Gray-Owen, Trevor F. Moraes |
| Novel vaccine antigens against |
TUFTS UNIVERSITY BOSTON Paola Massari |